Tom Frohlich
Private Equity Investor chez Versant Ventures Canada Ltd.
Profil
Tom Frohlich is currently an Entrepreneur-in-Residence at Versant Ventures Canada Ltd.
He previously held positions as Vice President-Business Development at Arbutus Biopharma Corp.
from 2016 to 2018, Senior Vice President-Business Development at Inception Sciences, Inc. in 2018, and Chief Business Officer at Chinook Therapeutics, Inc. from 2019 to 2021.
Mr. Frohlich has an MBA from the University of Oxford and an undergraduate degree from the University of Victoria.
Postes actifs de Tom Frohlich
Sociétés | Poste | Début |
---|---|---|
Versant Ventures Canada Ltd. | Private Equity Investor | - |
Anciens postes connus de Tom Frohlich
Sociétés | Poste | Fin |
---|---|---|
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2018 |
ARBUTUS BIOPHARMA CORPORATION | Corporate Officer/Principal | 01/03/2018 |
CHINOOK THERAPEUTICS, INC. | Directeur des opérations | - |
Formation de Tom Frohlich
University of Oxford | Masters Business Admin |
University of Victoria | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
Entreprise privées | 3 |
---|---|
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Health Technology |
Versant Ventures Canada Ltd. | Finance |
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |